Gary Patou Biography and Net Worth

Director of Xenon Pharmaceuticals

Dr. Patou has served as a member of our Board since January 2004. Dr. Patou has served as a Chief Medical Officer at Star Therapeutics Inc. and as an Advisor at MPM Capital, a venture capital fund focused on life sciences companies, since August 2020. Dr. Patou has served as a member of the board of directors and Chief Medical Officer for BioIntervene Inc., a preclinicalstage biopharmaceutical company, since January 2019. Previously, Dr. Patou was an Executive Partner at MPM Capital from 2005 until 2020, and has served as interim Chief Medical Officer in various MPM portfolio companies, including at Blade Therapeutics from October 2018 to December 2020. Prior to joining MPM, Dr. Patou was Executive Vice President and Chief Medical Officer of Oscient Pharmaceuticals Corp. from February 2004 to April 2005 following its merger with GeneSoft Pharmaceuticals, Inc. Prior to GeneSoft, Dr. Patou worked at SmithKline Beecham Pharmaceuticals, now a unit of GlaxoSmithKline, as Senior Vice President and Director, Project and Portfolio Management, managing all of the company’s pharmaceutical development projects. Dr. Patou has held a number of academic appointments at University College & Middlesex School of Medicine and received his B.Sc. from University of London and his M.D. from University College London.

What is Gary Patou's net worth?: The estimated net worth of Gary Patou is at least $903,081.63 as of December 13th, 2023. Dr. Patou owns 23,573 shares of Xenon Pharmaceuticals stock worth more than $903,082 as of November 18th. This net worth approximation does not reflect any other assets that Dr. Patou may own. Learn More about Gary Patou's net worth.
How do I contact Gary Patou?: The corporate mailing address for Dr. Patou and other Xenon Pharmaceuticals executives is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. Xenon Pharmaceuticals can also be reached via phone at (604) 484-3300 and via email at [email protected]. Learn More on Gary Patou's contact information.
Has Gary Patou been buying or selling shares of Xenon Pharmaceuticals?: Gary Patou has not been actively trading shares of Xenon Pharmaceuticals during the last ninety days. Most recently, Gary Patou sold 11,380 shares of the business's stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $39.29, for a transaction totalling $447,120.20. Following the completion of the sale, the director now directly owns 23,573 shares of the company's stock, valued at $926,183.17. Learn More on Gary Patou's trading history.
Who are Xenon Pharmaceuticals' active insiders?: Xenon Pharmaceuticals' insider roster includes James Empfield (EVP), Steven Gannon (Director), Frank Holler (Director), Christopher Kenney (Insider), Ian Mortimer (President and Chief Executive Officer), Gary Patou (Director), Simon Pimstone (Director), Robin Sherrington (EVP), Dawn Svoronos (Director), and Christopher Von Seggern (Insider). Learn More on Xenon Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Xenon Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 31,517 shares worth more than $1,379,060.56. The most recent insider tranaction occured on March, 7th when EVP Sherrington Robin sold 7,137 shares worth more than $330,300.36. Insiders at Xenon Pharmaceuticals own 5.5% of the company. Learn More about insider trades at Xenon Pharmaceuticals.
Information on this page was last updated on 3/7/2024.

Gary Patou Insider Trading History at Xenon Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/13/2023	Sell	11,380	$39.29	$447,120.20	23,573
11/25/2022	Sell	1,937	$34.79	$67,388.23	23,573
11/23/2022	Sell	2,057	$34.33	$70,616.81	23,573
8/8/2017	Buy	5,000	$3.00	$15,000.00	12,028

Gary Patou Buying and Selling Activity at Xenon Pharmaceuticals

Xenon Pharmaceuticals Company Overview

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Today's Range

Now: $38.31

$37.38

$40.01

50 Day Range

MA: $41.21

$38.06

$45.74

2 Week Range

Now: $38.31

$28.20

$50.99

Volume

878,189 shs

Average Volume

389,378 shs

Market Capitalization

$2.92 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25

DeFi Coin on Verge of Breakout!

From Crypto 101 Media | Ad

The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years.

Claim your FREE book now before it's too late!